Andrew Farb, M.D. is the Chief Medical Officer in the Office of Cardiovascular Devices at FDA’s Center for Devices and Radiological Health (CDRH). He graduated from Dartmouth College (B.A.) and Cornell University Medical College (M.D.). He completed a fellowship in clinical cardiology at The New York Hospital–Cornell University Medical Center. Dr. Farb is board-certified in Internal Medicine and Cardiovascular Diseases. He has research interests in and multiple publications on cardiovascular pathology, coronary atherosclerosis and mechanisms of thrombosis, coronary artery interventions, and structural heart disease. He joined the FDA in 2004, where he has concentrated on clinical studies for interventional cardiology, structural heart, and peripheral vascular devices. Dr. Farb co-authored FDA’s Early Feasibility Study (EFS) Guidance document, and he is the Co-Leader of CDRH’s EFS Program. In addition to his position at FDA, he is an attending physician in clinical cardiology.